508 related articles for article (PubMed ID: 16597469)
1. The A/T-specific DNA alkylating agent adozelesin inhibits Plasmodium falciparum growth in vitro and protects mice against Plasmodium chabaudi adami infection.
Yanow SK; Purcell LA; Spithill TW
Mol Biochem Parasitol; 2006 Jul; 148(1):52-9. PubMed ID: 16597469
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomic analyses of targeting the AT-rich malaria parasite genome with AT-specific alkylating drugs.
Woynarowski JM; Krugliak M; Ginsburg H
Mol Biochem Parasitol; 2007 Jul; 154(1):70-81. PubMed ID: 17524501
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with a Plasmodium chabaudi adami multivalent DNA vaccine cross-protects A/J mice against challenge with P. c. adami DK and virulent Plasmodium chabaudi chabaudi AS parasites.
Scorza T; Grubb K; Cambos M; Santamaria C; Tshikudi Malu D; Spithill TW
Int J Parasitol; 2008 Jun; 38(7):819-27. PubMed ID: 18062974
[TBL] [Abstract][Full Text] [Related]
4. Delayed parasite elimination in human infections treated with clindamycin parallels 'delayed death' of Plasmodium falciparum in vitro.
Burkhardt D; Wiesner J; Stoesser N; Ramharter M; Uhlemann AC; Issifou S; Jomaa H; Krishna S; Kremsner PG; Borrmann S
Int J Parasitol; 2007 Jun; 37(7):777-85. PubMed ID: 17280676
[TBL] [Abstract][Full Text] [Related]
5. Antigen-specific, interleukin 2-propagated T lymphocytes confer resistance to a murine malarial parasite, Plasmodium chabaudi adami.
Brake DA; Weidanz WP; Long CA
J Immunol; 1986 Jul; 137(1):347-52. PubMed ID: 2423609
[TBL] [Abstract][Full Text] [Related]
6. Curcumin for malaria therapy.
Reddy RC; Vatsala PG; Keshamouni VG; Padmanaban G; Rangarajan PN
Biochem Biophys Res Commun; 2005 Jan; 326(2):472-4. PubMed ID: 15582601
[TBL] [Abstract][Full Text] [Related]
7. Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials.
Skinner-Adams TS; Stack CM; Trenholme KR; Brown CL; Grembecka J; Lowther J; Mucha A; Drag M; Kafarski P; McGowan S; Whisstock JC; Gardiner DL; Dalton JP
Trends Biochem Sci; 2010 Jan; 35(1):53-61. PubMed ID: 19796954
[TBL] [Abstract][Full Text] [Related]
8. Cleavage of DNA induced by 9-anilinoacridine inhibitors of topoisomerase II in the malaria parasite Plasmodium falciparum.
Auparakkitanon S; Wilairat P
Biochem Biophys Res Commun; 2000 Mar; 269(2):406-9. PubMed ID: 10708566
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Plasmodium falciparum cGMP-dependent protein kinase (PfPKG): antiparasitic activity of a PKG inhibitor.
Diaz CA; Allocco J; Powles MA; Yeung L; Donald RG; Anderson JW; Liberator PA
Mol Biochem Parasitol; 2006 Mar; 146(1):78-88. PubMed ID: 16325279
[TBL] [Abstract][Full Text] [Related]
10. Suppression of Plasmodium berghei parasitemia by LiCl in an animal infection model.
Nurul Aiezzah Z; Noor E; Hasidah MS
Trop Biomed; 2010 Dec; 27(3):624-31. PubMed ID: 21399604
[TBL] [Abstract][Full Text] [Related]
11. Enhanced activity of mefloquine and artesunic acid against Plasmodium falciparum in vitro and P. berghei in mice by combination with ciprofloxacin.
Andrade AA; de Pilla Varotti F; de Freitas IO; de Souza MV; Vasconcelos TR; Boechat N; Krettli AU
Eur J Pharmacol; 2007 Mar; 558(1-3):194-8. PubMed ID: 17214980
[TBL] [Abstract][Full Text] [Related]
12. Plasmodium falciparum: growth response to potassium channel blocking compounds.
Waller KL; Kim K; McDonald TV
Exp Parasitol; 2008 Nov; 120(3):280-5. PubMed ID: 18703053
[TBL] [Abstract][Full Text] [Related]
13. The in vitro anti-plasmodial and in vivo anti-malarial efficacy of combinations of some medicinal plants used traditionally for treatment of malaria by the Meru community in Kenya.
Gathirwa JW; Rukunga GM; Njagi EN; Omar SA; Mwitari PG; Guantai AN; Tolo FM; Kimani CW; Muthaura CN; Kirira PG; Ndunda TN; Amalemba G; Mungai GM; Ndiege IO
J Ethnopharmacol; 2008 Jan; 115(2):223-31. PubMed ID: 18065175
[TBL] [Abstract][Full Text] [Related]
14. Multidrug resistance is a component of V79 cell resistance to the alkylating agent adozelesin.
Bhuyan BK; Smith KS; Kelly RC; Adams EG; Abraham I; Sampson KE
Cancer Res; 1993 Mar; 53(6):1354-9. PubMed ID: 8443816
[TBL] [Abstract][Full Text] [Related]
15. In vitro assessment of the pharmacodynamic properties of DB75, piperaquine, OZ277 and OZ401 in cultures of Plasmodium falciparum.
Hofer S; Brun R; Maerki S; Matile H; Scheurer C; Wittlin S
J Antimicrob Chemother; 2008 Nov; 62(5):1061-4. PubMed ID: 18669520
[TBL] [Abstract][Full Text] [Related]
16. A class of potent antimalarials and their specific accumulation in infected erythrocytes.
Wengelnik K; Vidal V; Ancelin ML; Cathiard AM; Morgat JL; Kocken CH; Calas M; Herrera S; Thomas AW; Vial HJ
Science; 2002 Feb; 295(5558):1311-4. PubMed ID: 11847346
[TBL] [Abstract][Full Text] [Related]
17. Plasmodium vivax: in vitro susceptibility of blood stages to synthetic trioxolane compounds and the diamidine DB75.
Kocken CH; van der Wel A; Arbe-Barnes S; Brun R; Matile H; Scheurer C; Wittlin S; Thomas AW
Exp Parasitol; 2006 Jul; 113(3):197-200. PubMed ID: 16458301
[TBL] [Abstract][Full Text] [Related]
18. Anti-plasmodial activity of the extracts of some Kenyan medicinal plants.
Rukunga GM; Gathirwa JW; Omar SA; Muregi FW; Muthaura CN; Kirira PG; Mungai GM; Kofi-Tsekpo WM
J Ethnopharmacol; 2009 Jan; 121(2):282-5. PubMed ID: 19041710
[TBL] [Abstract][Full Text] [Related]
19. Natural regulatory (CD4+CD25+FOXP+) T cells control the production of pro-inflammatory cytokines during Plasmodium chabaudi adami infection and do not contribute to immune evasion.
Cambos M; Bélanger B; Jacques A; Roulet A; Scorza T
Int J Parasitol; 2008 Feb; 38(2):229-38. PubMed ID: 17868677
[TBL] [Abstract][Full Text] [Related]
20. Potent antimalarial and transmission-blocking activities of centanamycin, a novel DNA-binding agent.
Yanow SK; Purcell LA; Pradel G; Sato A; Rodriguez A; Lee M; Spithill TW
J Infect Dis; 2008 Feb; 197(4):527-34. PubMed ID: 18275274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
